Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...
Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
The Top 5 Biosimilar Articles for the Week of December 2 ...
In an interview with Josh Canavan, PharmD, head of pharmacy at RazorMetrics, he discussed the role of pharmacy benefit managers (PBMs) in the biosimilar landscape. He emphasized the importance of PBMs ...
January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback